← Back to Search

Monoclonal Antibodies

BIIB132 for Spinocerebellar Ataxias

Phase 1
Waitlist Available
Research Sponsored by Biogen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 267

Summary

This trial tests the safety and effectiveness of BIIB132, an experimental drug, in patients with spinocerebellar ataxia type 3 (SCA3). The drug works by lowering a specific protein to slow disease progression.

Eligible Conditions
  • Spinocerebellar Ataxia Type 3

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 267
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 267 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with Adverse Events (AEs)
Number of Participants with Serious Adverse Events (SAEs)

Trial Design

5Treatment groups
Experimental Treatment
Group I: Cohort 5: BIIB132 Dose 5 or Matching PlaceboExperimental Treatment2 Interventions
Participants will be randomized to receive BIIB132 Dose 5 or matching placebo, IT, either Q4W or every 12 weeks (Q12W), up to Day 85 or every 8 weeks (Q8W) up to Day 57.
Group II: Cohort 4: BIIB132 Dose 4 or Matching PlaceboExperimental Treatment2 Interventions
Participants will be randomized to receive BIIB132 Dose 4 or matching placebo, IT, Q4W, up to Day 85.
Group III: Cohort 3: BIIB132 Dose 3 or Matching PlaceboExperimental Treatment2 Interventions
Participants will be randomized to receive BIIB132 Dose 3 or matching placebo, IT, Q4W, up to Day 85.
Group IV: Cohort 2: BIIB132 Dose 2 or Matching PlaceboExperimental Treatment2 Interventions
Participants will be randomized to receive BIIB132 Dose 2 or matching placebo, IT, Q4W, up to Day 85.
Group V: Cohort 1: BIIB132 Dose 1 or Matching PlaceboExperimental Treatment2 Interventions
Participants will be randomized to receive BIIB132 Dose 1 or matching placebo, intrathecally (IT), every 4 weeks (Q4W), up to Day 85.

Find a Location

Who is running the clinical trial?

BiogenLead Sponsor
645 Previous Clinical Trials
467,385 Total Patients Enrolled
2 Trials studying Spinocerebellar Ataxias
168 Patients Enrolled for Spinocerebellar Ataxias
Medical DirectorStudy DirectorBiogen
2,881 Previous Clinical Trials
8,088,194 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top